PEMETREXED INTAS pemetrexed (as disodium) 1000 mg powder for injection vial

Active ingredient:

pemetrexed disodium, Quantity: 1102.9 mg (Equivalent: pemetrexed, Qty 1000 mg)

Available from:

Accord Healthcare Pty Ltd

INN (International Name):

pemetrexed disodium

Pharmaceutical form:

Injection, powder for

Composition:

Excipient Ingredients: mannitol; sodium hydroxide; hydrochloric acid

Administration route:

Intravenous

Units in package:

1 vial per carton

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Malignant Pleural Mesothelioma,Pemetrexed, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma.,Non-Small Cell lung Cancer,Pemetrexed in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.,Pemetrexed as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Product summary:

Visual Identification: A white to either light yellow or greenish yellow lyophilized solid in a clear glass vial; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2015-05-28